| Previous close | 14.00 |
| Open | 13.98 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 13.92 - 14.00 |
| 52-week range | 8.56 - 14.48 |
| Volume | |
| Avg. volume | 664 |
| Market cap | 175.017M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 43.75 |
| EPS (TTM) | 0.32 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.50 |
- Business Wire
Aelis Farma Announces its 2023 Financial Calendar
BORDEAUX, France, January 31, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its indicative financial calendar for the financial year 2023.
- Business Wire
Aelis Farma Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome
BORDEAUX, France, December 16, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today the recruitment of the first patient for its phase 1/2 trial of AEF0217 in participants with Down syndrome.
- Business Wire
Aelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders
BORDEAUX, France, November 15, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today positive results from its phase 1 clinical trials in healthy volunteers with its drug candidate AEF0217. AEF0217 is being developed for the treatment of cognitive deficits caused by a hyperactivity of the CB1 receptor, and as a first indi
